Studying plant-derived coumarins for their pharmacological and therapeutic properties as potential anticancer drugs

Expert Opinion on Drug Discovery

Volumn 2, Issue 12, 2007, Pages 1605-1618

  Kostova, Irena ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Breast cancer; Coumarins; Liver; Lung cancer; Pancreatic cancer; Prostate cancer

Indexed keywords

3 ARYL 4 HYDROXYCOUMARIN; 4 BENZYYL 3(4 CHLOROPHENYL) 7 METHOXYCOUMARIN; 665 COUMATE; 666 COUMATE; 668 COUMATE; AFLATOXIN B1; ALANINE AMINOTRANSFERASE; ANGELICA GIGAS EXTRACT; CASPASE 3; CIMETIDINE; COUMARIN; COUMARIN 3 (N ARYL)CARBOXAMIDE; COUMESTROL; DECURSIN; DICOUMAROL; ESCULETIN; FUROCOUMARIN; HYMECROMONE; ISOIMPERATORIN; ISOPIMPINELLIN; METHOXSALEN; NOVOBIOCIN; OSTHOLE; PENTOSALEN; PYRANOCOUMARIN DERIVATIVE; STX 64; SURAMIN; UMBELLIFERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; EXPERIMENTAL STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER PROTECTION; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; PANCREAS CANCER; PHARMACOPHORE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SMOKING; TONKA BEAN;

EID: 37349017558     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.12.1605     Document Type: Review

References (108)

1. KOSTOVA I: Synthetic and natural coumarins as cytotoxic agents. Curr. Med. Chem. Anticancer Agents (2005) 5(1):29-46.
2. LACY A, O'KENNEDY R: Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr. Pharm. Des. (2004) 10(30):3797-3811.
3. CURINI M, CRAVOTTO G, EPIFANO F, GIANNONE G: Chemistry and biological activity of natural and synthetic prenyloxycoumarins. Curr. Med. Chem. (2006) 13(2):199-222.
4. SANTANA L, URIARTE E, ROLEIRA F, MILHAZES N, BORGES F: Furocoumarins in medicinal chemistry. synthesis, natural occurrence and biological activity. Curr. Med. Chem. (2004) 11(24):3239-3261.
5. LOPEZ-GONZALEZ JS, PRADO-GARCIA H, AGUILAR-CAZARES D et al.: Apoptosis and cell cycle disturbances induced by coumarin and 7-hydroxycoumarin on human lung carcinoma cell lines. Lung Cancer (2004) 43(3):275-283.
6. TAKEUCHI H, SAOO K, YOKOHIRA M et al.: Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumourigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. Cancer Res. (2003) 63(22):7581-7583.
7. MIYAZAKI M, YAMAZAKI H, TAKEUCHI H et al.: Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas. Carcinogenesis (2005) 26(11): 1947-1955.
8. SELLERS EM, RAMAMOORTHY Y, ZEMAN MV et al.: The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine Tob. Res. (2003) 5:891-899.
9. VON WEYMARN LB, ZHANG QY, DING X et al.: Effects of 8-methoxypsoralen on cytochrome P450 2A13. Carcinogenesis (2005) 26(3):621-629.
10. WANG H, TAN W, HAO B et al.: Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res. (2003) 63(22):8057-8061.
11. TAKEUCHI H, SAOO K, MATSUDA Y et al.: Dose-dependent inhibitory effects of dietary 8-methoxypsoralen on NNK-induced lung tumourigenesis in female A/J mice. Cancer Lett. (2006) 234(2):232-238.
12. WANG R, KONG J, WANG D et al.: A survey of Chinese herbal ingredients with liver protection activities. Chin. Med. (2007) 2(5):1-8.
13. ZHANG Y, XIE M, ZHU L et al.: Therapeutic effect of osthole on hyperlipidemic fatty liver in rats. Acta Pharmacol. Sin. (2007) 28(3):398-403.
14. OKAMOTO T, KOBAYASHI T, YOSHIDA S: Synthetic derivatives of osthole for the prevention of hepatitis. Med. Chem. (2007) 3(1):35-44.
15. EGAN D, O'KENNEDY R, MORAN E et al.: The pharmacology, metabolism, analysis and applications of coumarin and coumarin-related compounds. Drug Metab. Rev. (1990) 22:503-529.
16. NATIONAL TOXICOLOGY PROGRAMME: Toxicology and carcinogenesis studies of coumarin (Cas No.91-64-5) in F344/N rats and B6C3F, mice (gavage studies). Technical Report No. NTP TR 422. NIH Publication No. 93-3153, US Department of Health and Human Services, NTH, Research Triangle Park, North Carolina, USA (1993).
17. FENTEM JH, FRY JR: Species differences in the metabolism and hepatotoxicity of coumann. Comp. Biochem. Physiol. (1993) 104:1-8.
18. UENO I, HIRONO I: Non-carcinogenic response to coumarin in Syrian golden hamsters. Food Chem. Toxicol. (1981) 19:353-355.
19. COX D, O'KENNEDY R, THOMES RD: The rarity of liver toxicity in patients treated with coumarin (1,2-benzopyrone). Hum. Toxicol. (1989) 8:501-506.
20. LAKE BG, EVANS JG, LEWIS DFV et al.: Studies on the acute effects of coumarin and some coumarin derivatives in the rat. Food Chem. Toxicol. (1994) 32:357-363.
21. COTTRELL S, OLIVER K, LAKE BG et al.: Strain-specific enhancement or inhibition of coumarin hepatotoxicity in mice following pretreatment with two different liver enzyme-inducing agents. Fund. Appl. Toxicol. (1996) 34:47-55.
22. OKAMOTO T, KAJINO K, HINO O: Hepatoprotective drugs for the treatment of virus-induced chronic hepatitis: from hypercarcinogenic state to hypocarcinogenic state. Jpn J. Pharmacol. (2001) 87(3):177-180.
23. OKAMOTO T, KOBAYASHI T, YOSHIDA S: Chemical aspects of coumarin compounds for the prevention of hepatocellular carcinomas. Curr. Med. Chem. Anticancer Agents (2005) 5(1):47-51.
24. THATI B, NOBLE A, CREAVEN BS et al.: A study of the role of apoptotic cell death and cell cycle events mediating the mechanism of action of 6-hydroxycoumarin-3-carboxylatosilver in human malignant hepatic cells. Cancer Lett. (2007) 250(1):128-139.
25. STEFFAN B, WÄTJEN W, MICHELS G et al.: Polyphenols from plants used in traditional Indonesian medicine (Jamu): uptake and antioxidative effects in rat H4IIE hepatoma cells. J. Pharm. Pharmacol. (2005) 57(2):233-240.
26. HAYES JD, PULFORD DJ, ELLIS EM et al.: Regulation of rat glutathione S-transferase A5 by cancer chemopreventive agents: mechanisms of inducible resistance to aflatoxin B1. Chem. Biol. Interact. (1998) 111-112:51-67.
27. SHEPHERD AG, MANSON MM, BALL HW et al.: Regulation of rat glutamate-cysteine ligase (γ-glutamylcysteine synthetase) subunits by chemopreventive agents and in aflatoxin B(1)-induced preneoplasia. Carcinogenesis (2000) 21 (10): 1827-1834.
28. KELLY VP, ELLIS EM, MANSON MM et al.: Chemoprevention of aflatoxin B1 hepatocarcinogenesis by coumarin, a natural benzopyrone that is a potent inducer of aflatoxin B1-aldehyde reductase, the glutathione S-transferase A5 and P1 subunits, and NAD(P)H:quinone oxidoreductase in rat liver. Cancer Res. (2000) 60(4):957-969.
29. POKHAREL YR, HAN EH, KIM JY et al.: Potent protective effect of isoimperatorin against aflatoxin B1-inducible cytotoxicity in H4IIE cells: bifunctional effects on glutathione S-transferase and CYP1A. Carcinogenesis (2006) 27(12):2483-2490.
30. MADARI H, PANDA D, WILSON L et al.: Dicoumarol: a unique microtubule stabilizing natural product that is synergistic with Taxol. Cancer Res. (2003) 63:1214-1220.
31. LEWIS A, OUGH M, LI L et al.: Treatment of pancreatic cancer cells with dicumarol induces cytotoxicity and oxidative stress. Clin. Cancer Res. (2004) 10:4550-4558.
32. CULLEN JJ, HINKHOUSE MM, GRADY M et al.: Dicumarol inhibition of NAD(P)H:quinone oxidoreductase (NQO1) induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. Cancer Res. (2003) 63:5513-5520.
33. LOGSDON CD, SIMEONE DM, BINKLEY C et al.: Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. (2003) 63:2649-2657.
34. SIEGEL D, ROSS D: Immunodetection of NQO1 in human tissues. Free Radic. Biol. Med. (2000) 29:246-253.
35. LARM JA, VAILLANT F, LINNANE AW et al.: Upregulation of the plasma membrane oxidoreductase as a prerequisite for the viability of human Namalwa rho 0 cells. J. Biol. Chem. (1994) 269:30097-30100.
36. BRAR SS, KENNEDY TP, WHORTON AR et al.: Reactive oxygen species from NAD(P)H: quinone oxidoreductase constitutively activate Nf-κB in malignant melanoma cells. Am. J. Physiol. (2001) 280:C659-C676.
37. EDLUND C, ELHAMMER A, DALLNER G: Distribution of newly synthesized DT-diaphorase in rat liver. Biosci. Rep. (1982) 2:861-865.
38. WINSKI SL, KOUTALOS Y, BENTLEY DL et al.: Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. Cancer Res. (2002) 62:1420-1424.
39. LI N, RAGHEB K, LAWLER G et al.: DPI induces mitochondrial superoxide-mediated apoptosis. Free Radic. Biol. Med. (2003) 34:465-477.
40. DU J, DANIELS DH, ASBURY C et al.: Mitochondrial production of reactive oxygen species mediate dicumarol-induced cytotoxicity in cancer cells. J. Biol. Chem. (2006) 281(49):37416-37426.
41. MOROHASHI H, KON A, NAKAI M et al.: Study of hyaluronan synthase inhibitor, 4-methylumbelliferone derivatives on human pancreatic cancer cell (KP1-NL). Biochem. Biophys. Res. Commun. (2006) 345(4):1454-1459.
42. SCHULZE H, SOMMERFELD HJ: Immunotherapy of prostate cancer. Urologe A (1993) 32(5):382-389.
43. YAGODA A, PETRYLAK D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer (1993) 71(3):1098-1109.
44. SINGH RP, AGARWAL R: Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer (2006) 13:751-778.
45. OMARBASHA B, HESTON WDW, HURYK R et al.: Treatment of metastatic prostate derived tumour with cimetidine and coumarin. J. Urol. (1988) 134:176.
46. OMARBASHA B, HESTON WDW, FAIR WR: Decrease prostatic size in response to coumarin treatment. Proc. Am. Assoc. Cancer Res. (1988) 29:372.
47. OMARBASHA B, FAIR WR, HESTON WDW: Effect of coumarin on the normal rat prostate and on the R-3327H prostatic adenocarcinoma. Cancer Res. (1989) 49:3045-3049.
48. MOHLER JL, WILLIAMS BT, THOMPSON IM et al.: Coumarin (1,2-benzopyrone) for the treatment of prostatic carcinoma. J. Cancer Res. Clin. Oncol. (1994) 120:S35-S38.
49. MOHLER JL, GOMELLA LG, CRAWFORD ED et al.: Phase II evaluation of coumarin (1,2-benzopyrone) in metastatic prostatic carcinoma. Prostate (1992) 20(2):123-131.
50. VON ANGERER E, KAGER M, MAUCHER A: Antitumour activity of coumarin in prostate and mammary cancer models. J. Cancer Res. Clin. Oncol. (1994) 120:S14-S16.
51. MYERS RB, PARKER M, GRIZZLE WE: The effects of coumarin and suramin on the growth of malignant renal and prostatic cell lines. J. Cancer Res. Clin. Oncol. (1994) 120:S11-S13.
52. MARSHALL ME, BUTLER K, HERMANSEN D: Treatment of hormone-refractory stage D carcinoma of prostate with coumarin (l,2-benzopyrone) and cimetidine: a pilot study. Prostate (1990) 17(2):95-99.
53. FELDMAN BJ, FELDMAN D: The development of androgen-independent prostate cancer. Nat. Rev. Cancer (2001) 1:34-45.
54. SINGH RP, AGARWAL R: Prostate cancer prevention by silibinin. Curr. Cancer Drug Targets (2004) 4:1-11.
55. BARNES S: Role of phytochemicals in prevention and treatment of prostate cancer. Epidemiol. Rev. (2001) 23:102-105.
56. NELSON PS, MONTGOMARY B: Unconventional therapy for prostate cancer: good, bad or questionable? Nat. Rev. Cancer (2003) 3:845-858.
57. DENMEADE SR, ISAACS JT: A history of prostate cancer treatment. Nat. Rev. Cancer (2002) 2:389-396.
58. LEE S, KANG SS, SHIN KS: Coumarins and pyrimidine from Angelica gigas roots. Nat. Prod. Sci. (2002) 8:58-61.
59. YIM D, SINGH RP, AGARWAL C et al.: A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res. (2005) 65(3):1035-1044.
60. PILAT MJ, KAMRADT JM, PIENTA KJ: Hormone resistance in prostate cancer. Cancer Metast. Rev. (1998) 17:373-381.
61. GUO J, JIANG C, WANG Z et al.: A novel class of pyranocoumarin anti-androgen receptor signalling compounds. Mol. Cancer Ther. (2007) 6:907-917.
62. KIM J-H, JEONG J-H, JEON S-T et al.: Decursin inhibits induction of inflammatory mediators by blocking NF-κB activation in macrophages. Mol. Pharmacol. (2006) 69(6):1783-1790.
63. SMITH IE, DOWSETT M: Aromatase inhibitors in breast cancer. N. Engl. J. Med. (2003) 348:2431-2442.
64. CHEN S, CHO M, KARLSBERG K et al.: Biochemical and biological characterization of a novel antiaromatase coumarin derivative. J. Biol. Chem. (2004) 279(46):48071-48078.
65. REED MJ, PUROHIT A, WOO LWL et al.: Steroid sulfatase: molecular biology, regulation and inhibition. Endocr. Rev. (2005) 26:171-202.
66. CIOBANU LC, LUU-THE V, MARTEL C et al.: Inhibition of estrone sulfate-induceduterine growth by potent non-estrogenic steroidal inhibitors of steroid sulfatase. Cancer Res. (2003) 63:6442-6446.
67. LI P-K, MILANO S, KLUTH L et al.: Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. (1996) 59:41-48:
68. UTSUMI T, YOSHIMURA N, TAKEUCHI S et al.: Elevated steroid sulfatase expression in breast cancer. J. Steroid Biochem. Mol. Biol. (2000) 73:141-145.
69. SANTNER SJ, FEIL PD, SANTEN RJ: In situ estrogen production via estrone sulfatase pathway in breast tumours: relative importance vs the aromatase pathway. J. Clin. Endocrinol. Metab. (1984) 59:29-33.
70. SUZUKI T, NAKATAT, MIKI Y et al.: Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res. (2003) 63:2762-2770.
71. PUROHIT A, WOO LW, CHANDER SK et al.: Steroid sulphatase inhibitors for breast cancer therapy. J. Steroid Biochem. Mol. Biol. (2003) 86(3-5):423-432.
72. RAOBAIKADY B, PUROHIT A, CHANDER SK et al.: Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyestradiol-bis-sulphamate. J. Steroid Biochem. Mol. Biol. (2003) 84(2-3):351-358.
73. IRESON CR, PARISH D, PUROHIT A et al.: Development of a sensitive high-performance liquid chromatography method for the detection of 667 COUMATE in vivo. J. Steroid Biochem. Mol. Biol. (2003) 84(2-3):337-342.
74. STANWAY SJ, PUROHIT A, WOO LW et al.: Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin. Cancer Res. (2006) 12(5):1585-1592.
75. LLOYD MD, PEDERICK RL, NATESH R et al.: Crystal structure of human carbonic anhydrase II at 1.95 A resolution in complex with 667-coumate, a novel anticancer agent. Biochem. J. (2005) 385(Part 3):715-720.
76. PUROHIT A, WOO LW, BARROW D et al.: Non-steroidal and steroidal sulfamates: new drugs for cancer therapy. Mol. Cell Endocrinol. (2001) 171(1-2):129-135.
77. WOO LI, PUROHIT A, MALINI B et al.: Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem. Biol. (2000) 7(10):773-791.
78. PUROHIT A, WOO LW, POTTER BV et al.: In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumours by 667 COUMATE. Cancer Res. (2000) 60(13):3394-3396.
79. PRINCE M, CAMPBELL CT, ROBERTSON TA et al.: Naturally-occurring coumarins inhibit 7, 12-dimethylbenz[a] anthracene DNA adduct formation in mouse mammary gland. Carcinogenesis (2006) 27(6):1204-1213.
80. KLEINER H, DIGIOVANNI J: Modifiers of cytochrome(s) P450. In: Cancer Chemoprevention Volume 1: Promising Cancer Chemopreventive Agents. Kelloff G, Hawk ET, Sigman CC (Eds), Humana Press, Tototwa, NJ, USA (2004).
81. LIN CC, LU YP, LOU YR et al.: Inhibition by dietary dibenzoylmethane of mammary gland proliferation, formation of DMBA-DNA adducts in mammary glands, and mammary tumourigenesis in Sencar mice. Cancer Lett. (2001) 168:125-132.
82. SINGLETARY KW, NELSHOPPEN JM, SCARDEFIELD S et al.: Inhibition by butylated hydroxytoluene and its oxidative metabolites of DMBA-induced mammary tumourigenesis and of mammary DMBA-DNA adduct formation in vivo in the female rat.Food Chem. Toxicol. (1992) 30:455-465.
83. ZHAO LC, TANG LJ, LI QL et al.: Advances on phytoestrogen intervening breast cancer. Zhongguo Zhong Yao Za Zhi (2006) 31(12):957-960.
84. CASSIDY A, BINGHAM S, SETCHELL K: Biological effects of isoflavones in young women: importance of the chemical composition of soyabean products. Br. J. Nutr. (1995) 74:587-601.
85. WATANABE S, TERASHIMA K, SATO Y et al.: Effects of isoflavone supplement on healthy women. Biofactors (2000) 12:233-241.
86. ADLERCREUTZ H: Phytoestrogens: epidemiology and a possible role in cancer protection. Environ. Health Perspect. (1995) 103(7):103-112.
87. MUELLER SO, SIMON S, CHAE K et al.: Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor α (ERα) and ERβ in human cells. Toxicol. Sci. (2004) 80():14-25.
88. MÄKELÄ S, POUTANEN M, LEHTIMÄKI J et al.: Estrogen-specific 17β-hydroxysteroid oxidoreductase type 1 (E.C. 1.1.1.62) as a possible target for the action of phytoestrogens. Proc. Soc. Exp. Biol. Med. (1995) 208(1):51-59.
89. LIMER JL, SPEIRS V: Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res. (2004) 6:119-127.
90. JACQUOT Y, LAÏOS I, CLEEREN A et al.: Synthesis, structure, and estrogenic activity of 4-amino-3-(2-methylbenzyl) coumarins on human breast carcinoma cells. Bioorg. Med. Chem. (2007) 15(6):2269-2282.
91. BURLISON JA, BLAGG BS: Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery. Org. Lett. (2006) 8(21):4855-4858.
92. WHITESELL L, MIMNAUGH EG, DE COSTA B et al.: Inhibition of heat-shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA (1994) 91:8324-8328.
93. MARCU MG, SCHULTE TW, NECKERS L: Novobiocin and related coumarins and depletion of heat-shock protein 90-dependent signalling proteins. J. Natl. Cancer Inst. (2000) 92(3):242-248.
94. WOO LW, PUROHIT A, REED MJ et al.: Active site directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates. J. Med. Chem. (1996) 39(7):1349-1351.
95. REDDY NS, GUMIREDDY K, MALLIREDDIGARI MR et al.: Novel coumarin-3-(N-aryl) carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1. Bioorg. Med. Chem. (2005) 13(9):3141-3147.
96. KIRKIACHARIAN S, CHIDIACK H, PHILIBERT D et al.: Binding affinity to steroid hormone receptors and antiproliferative action on MCF-7 cells of coumarin derivatives and isoflavonoids. Ann. Pharm. Fr. (1999) 57(4):332-339.
97. KOSHY L, DWARAKANATH BS, RAJ HG et al.: Suicidal oxidative stress induced by certain antioxidants. Indian J. Exp. Biol. (2003) 41(11):1273-1278.
98. FINN G, CREAVEN B, EGAN D: study of the in vitro cytotoxic potential of natural and synthetic coumarin derivatives by using human normal and neoplastic skin cell lines. Melanoma Res. (2001) 11:461-467.
99. FINN G, CREAVEN B, EGAN D: In vitro cytotoxic potential and mechanism of action of selected coumarins, using human renal cell lines. Cancer Lett. (2002) 183(1):61-68.
100. FINN G, CREAVEN B, EGAN D: Investigation of intracellular signalling events mediating the mechanism of action of 7-hydroxycoumarin and 6-nitro-7-hydroxycoumarin in human renal cells. Cancer Lett. (2003) 205(1):69-79.
101. FINN G, CREAVEN B, EGAN D: Activation of mitogen activated protein kinase pathways and melanogenesis by novel nitro-derivatives of 7-hydroxycomarin in human malignant melanoma cells. Eur. J. Pharm. Sci. (2005) 26(1):16-25.
102. FINN G, CREAVEN B, EGAN D: A study of the role of cell cycle events mediating the action of coumarin derivatives in human malignant melanoma cells. Cancer Lett. (2004) 214(1):43-54.
103. FINN G, CREAVEN B, EGAN D: Daphnetin induced differentiation of human renal carcinoma cells and its mediation by p38 mitogen-activated protein kinase. Biochem. Pharmacol. (2004) 67(9):1779-1788.
104. FINN G, CREAVEN B, EGAN D: Modulation of mitogen-activated protein kinases by 6-nitro-7-hydroxycoumarin mediates apoptosis in renal carcinoma cells. Eur. J. Pharmacol. (2003) 481(2-3):159-167.
105. PELKONEN O, RAUNIO H, RAUTIO A, PASANEN M, LANG MA: The metabolism of coumarin. In: Coumarins: Biology, Applications and Mode of Action. O'Kennedy R, Thornes RD (Eds), John Wiley & Sons Ltd., New York, USA (1997).
106. PELKONEN O, RAUTIO A, RAUNIO H, MÄENPÄÄ J, HAKKOLA J: Regulation of coumarin 7-hydroxylation in man. J. Cancer Res. Clin. Oncol. (1994) 120(1):S30-S31.
107. FARINOLA N, PILLER NB: CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients? Pharmacogenomics (2007) 8(2): 151-158.
108. LOPRINZI CL, KUGLER JW, SLOAN JA et al.: Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N. Engl. J. Med. (1999) 340:346-350.